Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

Abstract

Taxol has significant activity in ovarian cancer and should be studied in combination with other active agents earlier in this disease.

Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer

“…Paclitaxel, a newer taxane, has been shown to be effective against a variety of cancers, including breast cancer (Holmes et al, 1991), ovarian cancer (Einzig et al, 1992), and lung cancer (Chang et al, 1993). Paclitaxel is also an effective drug for gastric cancer, with response rates ranging from 20 to 28% in single-agent phase II studies (Ajani et al, 1998;Ohtsu et al, 1998;Yamada et al, 2001;Yamaguchi et al, 2002).…”

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease

“…schedule was a factor. The result of this study should be interpreted in the light of the published phase II studies of taxol in relapsed ovarian cancer (Einzig et al,1992;McGuire et al, 1989), in which a total of 70 patients have been treated with two complete and 16 partial responses (CR + PR 26%; 95% confidence intervals 16-38%). One of these studies excluded patients with more than one previous chemotherapy treatment.…”

“…Phase II studies in this situation, either with single agents (Sutton et al, 1989;Coleman et al, 1989;1990;Manetta et al, 1990) or with combination chemotherapy (Belinson et al, 1986; Benedetti-Panici et al, 1990;Pater et al, 1987), have generally yielded few responses, of short duration. Even the promising new agent, taxol, gives responses in only 20-30% of this group of patients (Einzig et al, 1992;McGuire et al, 1989; Trimble et al, 1993).Platinum-resistant cell lines show little or no crossresistance to etoposide in vitro, making it a potential candidate for use either in combination with platinum as primary treatment or, later, as second-line treatment for this disease. In the five previously reported studies using singleagent etoposide as second-line treatment, a total of 247 patients were treated, with 51 responses (complete and partial responses; 21%).…”

“…Phase II studies in this situation, either with single agents (Sutton et al, 1989;Coleman et al, 1989;1990;Manetta et al, 1990) or with combination chemotherapy (Belinson et al, 1986; Benedetti-Panici et al, 1990;Pater et al, 1987), have generally yielded few responses, of short duration. Even the promising new agent, taxol, gives responses in only 20-30% of this group of patients (Einzig et al, 1992;McGuire et al, 1989; Trimble et al, 1993).…”

Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group

“…The results of single agent epirubicin appear to be better in prior platinumexposed patients. Paclitaxel, an antimitotic agent derived from bark of Pacific Yew tree Taxus brevifolia (Schiff et al, 1979), proved to be active in relapsed and platinum-resistant ovarian cancer (McGuire et al, 1989;Einzig et al, 1992;Trimble et al, 1993;Kohn et al, 1994;Gore et al, 1995) and was well tolerated by most patients: significant side effects other than alopecia were uncommon (Seidman et al, 1996). Moreover, preliminary data in advanced breast cancer patients seemed to suggest that the combination of paclitaxel plus doxorubicin might have a potential interaction in efficacy (Gianni et al, 1994).…”